<DOC>
	<DOCNO>NCT02101008</DOCNO>
	<brief_summary>Primary Objectives Determine response rate associate treatment refractory disseminate malignant melanoma disulfiram chelate zinc . Secondary Objectives Determine progression-free survival associate treatment refractory disseminate malignant melanoma disulfiram chelate zinc . Determine overall survival associate treatment refractory disseminate malignant melanoma disulfiram chelate zinc . Determine toxicity associate treatment refractory disseminate malignant melanoma disulfiram chelate zinc Determine effect disulfiram chelate zinc vivo protein S-glutathionylation .</brief_summary>
	<brief_title>Disulfiram Chelated Zinc Rx Disseminated Mets Mel That Has Failed First Line Therapy</brief_title>
	<detailed_description />
	<mesh_term>Zinc</mesh_term>
	<mesh_term>Disulfiram</mesh_term>
	<criteria>The subject must fulfill follow inclusion criterion eligible participation study , unless otherwise specify : 1 . Male female patient stage IV melanoma cancer biopsy proven metastasis demonstrate image study . Extent disease document CT scan chest , abdomen pelvis , PET/CT scan . At least one site disease measurable RECIST criterion . 2 . Age 18 year 3 . ECOG performance status 0 2 4 . Patients must receive progressed respond least one cycle first line therapy ( chemotherapy , biotherapy , biochemotherapy ) unwilling ineligible undergo standard therapy 5 . Patients brain metastasis along disease site eligible participate brain disease treat surgery radiation 6 . Not currently receive cancer chemotherapy 7 . Not currently participate another study 8 . Baseline AST ALT great 2.0 X upper limit normal 9 . Able willing provide inform consent comply study procedures 10 . Able ingest oral medication 11 . No known allergy disulfiram zinc gluconate 12 . Willing refrain ingestion alcoholic beverage study 13 . Serum copper within normal range baseline , outside normal range , PI review clinical significance Potential study subject meet follow criterion eligible participation study : 1 . Participation another clinical trial therapeutic drug past 30 day 2 . Addiction alcohol cocaine 3 . Baseline AST ALT great 2.0 X upper limit normal 4 . Unable ingest oral medication 5 . Unable undergo CT scan inability lie recumbent scanner ; 6 . Actively receive cytotoxic cancer chemotherapy agent 7 . Evidence thiuram allergy ( may present contact allergy rubber elastic ) 8 . Current use sertraline cyclosporine 9 . Women childbearing potential use commonly accept effective mean contraception ; woman childbearing potential pregnancy test enrollment 10 . Need warfarin theophylline , metabolism likely influence disulfiram 11 . Pregnant woman nurse mother allow enroll study 12 . Patients take medication metabolize cytochrome P450 2E1 , include chlorzoxazone halothane derivative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>